South Korea Pharmaceuticals

SK Biopharmaceuticals Co Ltd (326030)

Track

Track

SK Biopharmaceuticals witnessed two executive purchases totaling 118.34 million KRW on September 15, 2026. The President and Head of Strategy Division acquired shares, reflecting net buying activity. This occurred while the stock price hovered near its 52-week low, preceding the upcoming November earnings report.
Ticker: 326030 Exchange: KSC
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Yu Chang Ho (유창호) Head of Strategy Division (전략부문장) Officer
Transaction date
Purchase
Price
159.76
Quantity 64,282 -8.1%
Value ₩26,535
I Dong Hun (이동훈) President (사장) Officer
Transaction date
Purchase
Price
253.26
Quantity 98,660 -14.8%
Value ₩348,462
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-15 2026-09-15 B Purchase Yu Chang Ho (유창호)

Head of Strategy Division (전략부문장)

Officer
64,282 -8.1%
159.76
₩26,535 		64,282 -8.1% 159.76 ₩26,535
2026-09-15 2026-09-15 B Purchase I Dong Hun (이동훈)

President (사장)

Officer
98,660 -14.8%
253.26
₩348,462 		98,660 -14.8% 253.26 ₩348,462
Explore more

More insider trading research around SK Biopharmaceuticals Co Ltd

More insider trades in South Korea
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in Asia-Pacific